Lantheus Holdings LNTH In Process Research And Development Included In Liabilities

In Process Research And Development Included In Liabilities at other companies

Spyre Therapeutics, Inc.SYRE

$30M—

Spyre Therapeutics, Inc.SYRE

$0—

BridgeBio PharmaBBIO

$54.43M+61.8%

Mid-America Apartment CommunitiesMAA

$75.26M+13.6%

BiogenBIIB

$35M—

AccentureACN

$204.33M-29.0%

Other financials

Income statement

See full

Revenue$377.3M+1.2%

Gross profit$230.9M-2.9%

Operating income$81.3M-20.3%

Net income$118.4M+62.3%

EPS (diluted)$1.80+76.5%

Balance sheet

See full

Cash & equivalents$500.3M-46.8%

Total debt$627.9M+1.8%

Total equity$1.2B+4.1%

Total assets$2.3B+14.2%

Cash flow

See full

Operating cash flow$125.1M+16.3%

CapEx$3.2M-63.0%

Free cash flow$121.9M+23.3%

Valuation

See full

Market cap$6.76B-26.3%

Enterprise value$6.89B-20.5%

P/E24.2×-10.2×

P/S4.4×-1.6×

Profitability

See full

Gross margin60.5%-3.6pp

Operating margin18.8%-10.7pp

Net margin18%+0.7pp

FCF margin24.4%-6.4pp

Returns & leverage

See full

Return on equity23.5%-1.7pp

Debt / equity0.5×0.0×

Current ratio2.8×-2.9×

Where this comes from

Reported directly by Lantheus Holdings in its filing.

Tagged under the XBRL concept lnth:InProcessResearchAndDevelopmentIncludedInLiabilities.

The official record: Lantheus Holdings’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Lantheus Holdings's in process research and development included in liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Lantheus Holdings's in process research and development included in liabilities?: Lantheus Holdings (LNTH) reported in process research and development included in liabilities of $1.45M in Q4 2025.
What does in process research and development included in liabilities mean?: This represents the portion of acquisition-related consideration that is contingent upon the future success or development milestones of acquired R&D projects. It reflects the company's future financial commitments tied to the progress of its innovation pipeline. This metric is vital for assessing the long-term financial risk and potential upside associated with recent acquisitions.